October 21, 2016

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: 
Annals of Surgical Oncology; March 2017, Volume 24, Issue 3; pp 669–675.

AUTHORS: 
Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V. Pellicane, Charles Nash, Mary Murray, Laura A. Lee, Carrie L. Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A. de Snoo, Jennifer Beatty

ABSTRACT: 
Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for determining optimal treatment. In the Neoadjuvant Breast Registry Symphony Trial (NBRST) patients were classified according to MammaPrint/BluePrint subtyping to provide insight into the response to neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NCT).

The purpose of this predefined substudy was to compare MammaPrint/BluePrint with conventional ‘clinical’ immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) subtyping in ‘clinical luminal’ [HR+/human epidermal growth factor receptor 2-negative (HER2−)] breast cancer patients to predict treatment sensitivity.

NBRST IHC/FISH HR+/HER2− breast cancer patients (n = 474) were classified into four molecular subgroups by MammaPrint/BluePrint subtyping: Luminal A, Luminal B, HER2, and Basal type. Pathological complete response (pCR) rates were compared with conventional IHC/FISH subtype.

Read more: Annals of Surgical Oncology_Mar 2017